- Report
- October 2022
- 199 Pages
Global
From €3223EUR$3,600USD£2,745GBP
- Report
- September 2022
- 118 Pages
Middle East, Africa
From €1343EUR$1,500USD£1,144GBP
- Report
- November 2021
- 230 Pages
Global
From €3223EUR$3,600USD£2,745GBP
- Report
- October 2022
- 65 Pages
Global
From €3536EUR$3,950USD£3,012GBP
- Report
- December 2023
- 319 Pages
Global
€4472EUR$4,995USD£3,809GBP
- Report
- September 2023
- 114 Pages
Global
From €2641EUR$2,950USD£2,249GBP
- Report
- September 2023
- 89 Pages
From €2641EUR$2,950USD£2,249GBP
- Report
- September 2023
- 107 Pages
Asia Pacific
From €3088EUR$3,450USD£2,631GBP
- Report
- September 2023
- 101 Pages
North America
From €2641EUR$2,950USD£2,249GBP
- Report
- September 2023
- 194 Pages
Global
From €4431EUR$4,950USD£3,774GBP
- Report
- December 2022
- 114 Pages
Global
€6714EUR$7,500USD£5,719GBP
- Report
- March 2021
- 137 Pages
Global
From €4386EUR$4,900USD£3,736GBP
- Report
- March 2025
- 92 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- March 2024
- 112 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- April 2023
- 91 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- October 2023
- 99 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- October 2023
- 146 Pages
Global
From €3715EUR$4,150USD£3,164GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more